Dr. Xiaomin (Jasmine) Su

Jasmine focuses her practice on strategic patent counseling and prosecution for clients in the biotechnology, pharmaceutical, and medical device industries. She advises on global patent strategies and life cycle management, helping companies maximize IP value from early-stage innovation through commercialization.

Jasmine brings deep technical experience and industry insight, particularly in cutting-edge areas such as antibody therapies, gene therapies, CAR-T cell therapies, CRISPR gene editing, RNA-based therapeutics, peptide therapies (including GLP-1), small molecule drugs, NGS diagnostics, and minimally invasive medical devices.

Before joining Cooley, Jasmine practiced at a leading DC law firm. She earned her PhD in immunology and microbiology from the University of Rochester, where her research focused on neurodegenerative diseases, and completed postdoctoral training at the University of California San Francisco, developing gene therapies for Parkinson’s disease.  

Jasmine’s representative matters include:

• Metsera, Inc. – Patent prosecution and IP diligence supporting its $275 million IPO and subsequent $10 billion acquisition by Pfizer
• Mammoth Biosciences – Patent prosecution and counseling for CRISPR-based therapeutics and diagnostics
• Aptevo Therapeutics – Patent prosecution and counseling for antibody and multi-specific antibody therapies
• Jazz Pharmaceuticals – Orange Book patent strategy and prosecution
• AtaiBeckley Inc.– Patent prosecution and counseling for clinical-stage psychedelic therapeutics
• Rocket Pharmaceuticals – Patent prosecution and counseling for lentiviral gene therapies
• Swiss Rocket – IP diligence for licensing deals with Complete Genomics (MPS/NGS technology)
• Shenzhen MagicRNA – IP diligence for LNP delivery of RNA therapies
• Windward Bio – IP diligence for licensing bispecific antibody technology
• Function Health, Inc. – IP diligence for acquisition related to blood testing technology
• Celgene – Patent prosecution and counseling for small molecule anti-cancer drugs*
• MicroSurgical Technology (MST) – Patent prosecution and counseling for eye surgery devices*
  *Representation handled prior to joining Cooley)

Speaking engagements

• Presenter, “Building a Deal-Ready Patent Portfolio: What Licensors, Investors, and Pharma Partners Actually Want,” HKU IP Day, Hong Kong, May 19, 2026
• Presenter, “How Life and Health Companies Benefit from HK IP & Licensing,” HKSTP Market Discovery BIO Connect, Hong Kong, May 13, 2026
• Presenter, “Intellectual Property Risk Identification and Response Strategies,” The Chinese Biopharmaceutical Association CBA-China Annual Conference, Wuxi, China, May 10, 2026
• Panelist, “Patent Policy Crossroads: Access, Innovation, and the Global Health Pipeline,” American University Washington College of Law IP Brief Symposium, Washington DC, April 10, 2026